Apollo Health and Vielight have formed a strategic partnership to support participants of the Bredesen Protocol with Vielight’s brain photobiomodulation technology.
Learn about the advantages of offering our Vielight Neuro Gamma technology to your clients for home-use through our Apollo Health partnership reseller program.
Our clinical research in dementia suggests improvements in cognition and memory.
Engineered for simplicity, integrating Vielight technology for client home-use is easy.
Engineered for optimal brain stimulation.
The Vielight Neuro Gamma directs 810nm NIR light energy pulsed at 40Hz into the brain’s Default Mode Network.
*The 810nm wavelength provides the highest energy deposition in a study by Harvard Medical School.
*Gamma brain waves have correlations with Alzheimer’s disease: Link
The ventromedial prefrontal cortex is a main hub of the DMN
Our patented intranasal technology enables access to it through the nose.
People with Alzheimer’s disease show disruptions of functional connectivity within the Default Mode Network (DMN).[1]
Brain photobiomodulation with the Neuro Gamma increased connectivity between nodes within the DMN in an fMRI-based research study by the University of California San Francisco.[2]
[1] Grieder M, Wang DJJ, Dierks T, Wahlund LO, Jann K. Default Mode Network Complexity and Cognitive Decline in Mild Alzheimer’s Disease. Front Neurosci. 2018 Oct 23;12:770. doi: 10.3389/fnins.2018.00770. PMID: 30405347; PMCID: PMC6206840.
[2]Chao LL. Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photobiomodul Photomed Laser Surg. 2019 Mar;37(3):133-141. doi: 10.1089/photob.2018.4555. Epub 2019 Feb 13. PMID: 31050950.
Add the Vielight Neuro Gamma to complement the Bredesen protocol.
10% discount code: “APOLLO” (automatically applied from product link)
Recommended protocol based on our phase 3 clinical trial: 6x a week, auto-timed 20 minutes.
Our quantity-based reseller program is also open to Apollo Health practitioners for resale of Vielight devices to clients.
Infrared capture of penetration and dispersion of 810nm light energy through a human cadaver.
Source: Infrared camera capture
Institut für EEG Neurofeedback IFEN
Source: University of California San Francisco.
Default-mode network activity in the PBM group—(A) baseline and (B) week 12 and in the usual care group—(C) baseline and (D) week 12. The posterior cingulate cortex (1, -61, and 38) was used as seed in the analysis; Height threshold: Punc < 0.001; cluster threshold PFDR < 0.05.
An overview of Alzheimer’s research with the Vielight Neuro Gamma.
First Alzheimer’s study
Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Photobiomodulation
Co-authoring institutes – Harvard Medical School, Boston University School of Medicine
[ Published Study ( 2015) ]
University of California – Independent Study
Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function and Resting-State Functional Connectivity in Patients with Dementia
Institutes – University of California San Francisco & the Veterans Affairs USA
[ Published Study (2018) ]
to present
Vielight Neuro RX Gamma – Pivotal Phase III Clinical Trial
Co-institutes – St Michael’s Hospital, Toronto
[ Clinical Trial Information Link ] (228 participants | 3 years | Ongoing)
Revitalizing Cognition in Older Adults at Risk for Alzheimer’s Disease With Near-Infrared Photobiomodulation
Institutes – University of Florida, University of Arizona, National Institute on Aging (NIA)
[ Clinical Trial Information Link ] (168 participants | 5 years | Registration)
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer’s Disease
Institutes – University of California San Francisco
[ Clinical Trial Information Link / UCSF Clinical Trials ] (16 participants | 1.5 years | Ongoing)
Join our Vielight reseller program to gain access to our reseller discount structure and premium support.
Discount structure: 30-45% discount off MSRP (volume dependent)
Recommended protocol based on our phase 3 clinical trial: 6x a week, auto-timed 20 minutes.
Contact us and mention you are an Apollo Health practitioner to learn more.
Quick facts.
Vielight’s high-powered LED systems are proprietary and developed internally. Each transcranial LED has an industry-leading power of 1000 mW. These sophisticated LEDs have their own drivers and are not available to other companies. It allows us to program radiant power density of up 300 mW/cm2. Although we are currently limiting it to 100 mW/cm2 for safety reasons, we still lead the entire industry. Our declared values for radiant power density are verified through medical-grade testing and manufacturing certifications.
Additionally, our lenses were engineered with curvature to maximize contact with the scalp and bypass hair. This maximizes power density, as the amount of light energy that reaches the scalp can be hindered by hair and distance, according to the inverse square law of light.
Literature and our ongoing research with institutional research partners show that radiant power density is one of the most important variables for optimal penetration, besides wavelength.
Our patented intranasal technology enables photobiomodulation of the olfactory bulb and ventral brain structures.
The Neuro’s modules locations are adjustable, enabling different areas of the brain to be targeted.
Flexible form factor maximizes contact of diodes with the scalp – bypassing hair and optimizing NIR light energy penetration.
In the field of brain photobiomodulation, our technology is featured in the most published research – spanning from neurodegeneration to brain performance. This is because we have been around the longest and have invested the most in advancing the field of brain photobiomodulation.
The Vielight Neuro Gamma is the only brain photobiomodulation device to induce Gamma neuromodulation in a peer-reviewed published study in a high impact journal.[1] Gamma neuromodulation is being researched by MIT and has been shown to improve brain function in humans with dementia.[2]
Besides that, improved brain connectivity and cerebral blood flow in an independent fMRI-based dementia study, which is the gold standard for determining physiological changes.[3]
[1] Zomorrodi R, Loheswaran G, Pushparaj A, Lim L. Pulsed Near Infrared Transcranial and Intranasal Photobiomodulation Significantly Modulates Neural Oscillations: a pilot exploratory study. Sci Rep. 2019 Apr 19;9(1):6309. doi: 10.1038/s41598-019-42693-x. PMID: 31004126; PMCID: PMC6474892.[2] Chan D, Suk HJ, Jackson BL, Milman NP, Stark D, Klerman EB, Kitchener E, Fernandez Avalos VS, de Weck G, Banerjee A, Beach SD, Blanchard J, Stearns C, Boes AD, Uitermarkt B, Gander P, Howard M 3rd, Sternberg EJ, Nieto-Castanon A, Anteraper S, Whitfield-Gabrieli S, Brown EN, Boyden ES, Dickerson BC, Tsai LH. Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies. PLoS One. 2022 Dec 1;17(12):e0278412. doi: 10.1371/journal.pone.0278412. PMID: 36454969; PMCID: PMC9714926.[3] Chao LL. Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial. Photobiomodul Photomed Laser Surg. 2019 Mar;37(3):133-141. doi: 10.1089/photob.2018.4555. Epub 2019 Feb 13. PMID: 31050950.
Medical grade certified by ISO13485 and MDSAP.
